Sugammadex: A Revolution in Neuromuscular Blockade Reversal

Authors

  • Kundra TS Deptt of Anaesthesia & ICU, Govt. Medical College, Patiala

Keywords:

Sugammadex, Neuromuscular blocker reversal, Rocuronium

Abstract

Sugammadex represents a significant advancement in anesthetic pharmacology, offering a rapid, safer and more reliable method for reversing NMB. Its unique pharmacologic profile, mechanism of action, favorable pharmacokinetic profile, and clinical efficacy make it a valuable tool in modern anesthesia practice and enhances patient safety and operating room efficiency. While it offers several advantages over traditional reversal agents, including reduced risk of residual NMB and PONV, clinicians should be aware of potential adverse effects and carefully consider patient-specific factors, including renal function and cardiovascular status, when using sugammadex to optimize its use and minimize potential risks.

Downloads

Download data is not yet available.

References

1. Yang LPH, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs 2009; 69: 919-42.

2. Lee HY, Jung KT. Advantages and pitfalls of clinical application of sugammadex. Anesth Pain Med (Seoul) 2020; 15: 259-68.

3. Chakravarthy VA, Sailaja BBV, Kumar AP. Method development and validation of ultraviolet-visible spectroscopic method for the estimation of assay of sugammadex sodium, apremilast, riociguat, and vorapaxar sulfate drugs in active pharmaceutical

ingredient form. Asian Journal of Pharmaceutical and Clinical Research 2017; 10: 241-50.

4. Sugammadex [Internet]. Wikipedia. Available from: en.wikipedia.org/wiki/Sugammadex [Accessed on 11-06-2025].

5. Chandrasekhar K, Togioka BM, Jeffers JL. (2023). Sugammadex [Internet]. National Library of Medicine. Available from: ncbi.nlm.nih.gov/sites/books/NBK470263/ [Accessed on 11-06-2025].

6. Mitchell C, Lobaz S. (2025). An Overview of Sugammadex [Internet]. World Federation of Societies of Anaesthesiologists. Available from: resources.wfsahq.org/atotw/an-overview-of-sugammadex/ [Accessed on 11-06-2025].

7. Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy. Sugammadex: A revolutionary drug in neuromuscular pharmacology. Anesth Essays Res 2013; 7: 302-6.

8. Lee W. The potential risks of sugammadex. Anesthesia and Pain Medicine 2019; 14: 117-22.

9. Ju J, Hwang IE, Cho H, Yang SM, Kim WH, Lee H. Effects of sugammadex versus neostigmine on postoperative nausea and vomiting after general anesthesia in adult patients: a single-center retrospective study. Sci Rep 2023; 13: 5422.

10. Kaye AD, Villafarra EA, Everett ES, Ware EE, Mashaw SA, Brouillette WD, et al. Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review. Heliyon 2025; 11: e41757.

11. Gurunathan U, Kunju SM, Stanton LML. Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports. BMC Anesthesiology 2019; Article Number: 213.

12. DeRuiter J, Holston PL, DeRuiter TJ. Review of selected NMEs 2016. US Pharm 2016; 41: HS8-14.

Downloads

Published

01-01-2026

How to Cite

Kundra, T. S. (2026). Sugammadex: A Revolution in Neuromuscular Blockade Reversal. GMC Patiala Journal of Research and Medical Education, 8(02), 36–39. Retrieved from https://jrme.gmcpatiala.edu.in/index.php/j/article/view/211

Issue

Vol. 8 No. 02 (2025): JUL-DEC

Section

Review Article

License

Copyright (c) 2026 Kundra TS

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.